Knobbe Martens client Pinnacle Spine Group, LLC, a developer of innovative spinal fusion systems, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,216,096 titled Intervertebral Implants and Related Tools. This patent is the third issued in the U.S. covering Pinnacle Spine’s innovative InFill® fusion technology.
The new patent is directed to systems that promote enhanced spinal fusion irrespective of implant type or approach. This patent considerably strengthens the patent coverage provided by the Company’s previous patents relating to the Infill® Fusion technology and is part of the Company’s larger portfolio of U.S. and International filings. The Company’s prior patents relate to spinal implants and methods of post-filling to provide for superior fusion results.
“This new patent significantly broadens our overall intellectual property portfolio and, from a commercial standpoint, meaningfully strengthens our patent position in the area of spinal fusion,” said Zach Sowell, President of Pinnacle Spine. Mr. Sowell added that “Pinnacle Spine plans to continue to work with surgeons and partners to improve the Company’s systems and promote the promising technology behind the InFill® family of fusion systems. We believe that maximizing contact between graft and a well-prepared endplate is the best way to promote a robust fusion. The industry clearly agrees, as we are seeing more and more devices and systems adopting in-situ graft delivery. We are proud to be trend setters and look forward to a year of growth in 2016, with many exciting projects already underway.”
About Pinnacle Spine Group, LLC
Based in Dallas, Texas, Pinnacle Spine Group, LLC is a privately held medical device company that develops and markets innovative technologies to improve the safety and efficiency of many spinal fusion procedures. The Company’s family of FDA-approved InFill® Fusion systems provides for superior results through the endplate to endplate contact of graft material achieved by post-filling implants after they have been delivered into targeted intervertebral spaces.
